🧬 Not the iPS cells — but the liquid they were grown in.

Injected into arthritic knees: 71.4% improved. Zero side effects.

A world-first clinical study that could help 375M people.

#iPSCells #RegenerativeMedicine #Osteoarthritis

Congrats to the REPROCELL team on launching its new StemEdit Platform, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system.

Read more: bioinformant.com/reprocell-st...

#ipscells #geneediting #ai

Japan Approves First iPS Cell-Based Products for Treating Heart Failure and Parkinson's Disease Japan's Ministry of Health, Labor and Welfare has granted conditional approval to two innovative regenerative medicine products derived from induced pluripotent stem (iPS) cells, marking the world's first authorizations of their kind. Announced on March 6, 2026, this milestone coincides with the 20th anniversary of Shinya Yamanaka's pioneering creation of mouse iPS cells at Kyoto University. iPS cells are reprogrammed adult cells that can differentiate into any cell type, offering immense potential for regenerative medicine without the ethical issues of embryonic stem cells. The first approved product is ReHeart by Qualipse, consisting of cardiomyocyte sheets grown from donor iPS cells. Intended for patients with severe heart failure from ischemic cardiomyopathy, the treatment involves attaching three cell sheets to the heart surface during surgery. These cells secrete signaling proteins that enhance blood flow and promote tissue repair. Early clinical data from a multicenter study showed promising improvements in peak oxygen consumption for some patients. The second product, Amusepri (laguneprocell) developed by Sumitomo Pharma and Racthera, features progenitor cells that develop into dopamine-producing neurons. Aimed at Parkinson's disease patients unresponsive to standard drugs like levodopa, it is implanted directly into the brain through small skull holes using minimally invasive techniques. Physician-led trials at Kyoto University demonstrated motor symptom improvements and confirmed cell viability at the transplant site. Manufacturing will occur at SMaRT, the world's first commercial facility for donor iPS cell-derived therapies in Osaka Prefecture. The iPS cells originate from Kyoto University's stock, supported by extensive industry-academia collaborations. These conditional approvals require ongoing post-marketing studies for safety and efficacy verification, a Japanese regulatory feature that accelerates access in complex fields like regenerative medicine. This development highlights Japan's integrated ecosystem, from basic research to production and policy support. While treatments will initially be limited and insurance coverage is pending, experts view this as the start of broader applications for iPS technology in medicine. Yamanaka and other researchers emphasize proceeding with scientific caution to ensure long-term success.

Japan Approves First iPS Cell-Based Products for Treating Heart Failure and Parkinson's Disease

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#ipscells #regenerativemedicine #stemcells

View full AI summary:

💉 What if diabetes patients never had to inject insulin again?
Japan's Orizuru Therapeutics completed the world's first transplant of iPS cell-derived islet cells. A woman with 20+ yrs of Type 1 diabetes received treatment in Feb 2025.
#iPSCells #RegenerativeMedicine #Diabetes

🧬 HISTORIC: Japan approved the world's first iPS cell therapies as products.
"ReHeart" — cell sheet repairing damaged hearts
"Amshepri" — dopamine neurons for Parkinson's
20 years from Yamanaka's Nobel discovery to real medicine.
#iPSCells #StemCell #RegenerativeMedicine

First-of-a-kind stem-cell therapies set for approval in Japan Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Nature comment: two first #iPSCells medicines got conditional approval after treating only 7–8 patients

Smart acceleration or risky precedent?

buff.ly/2PgcKWj

📣 📣 📣 World first!!

Japan’s health ministry has granted a provisional 7-year approval for the commercialization of two regenerative medicine products derived from #iPSCells, aimed at treating ischemic cardiomyopathy and Parkinson’s disease.
buff.ly/nAKKmib

🧬 Why are human legs longer than arms, but chimps have the opposite?
Kyoto & Hiroshima Univ. grew the world's first ape limb precursor cells from iPS stem cells — bonobos, chimps & gibbons.
Their "Whole-Zoo iPS Project" turns zoos into genetic libraries.
#iPSCells #StemCell

👁️ World first: Japan begins clinical trials for corneal regeneration using donor-derived iPS cells.
Reimei, an Osaka University spinoff, is testing iPS cell sheets to restore sight. If it works, this could end the global cornea donor shortage.
#iPSCells #RegenerativeMedicine

🧬WORLD FIRST: Japan approves 2 iPS cell products
🫀ReHeart: cardiac sheets for heart failure
🧠Amshepri: cell transplant for Parkinson's
20yrs after Yamanaka's Nobel discovery, iPS cells finally reach patients.
What's regen medicine like in YOUR country?
#iPSCells #iPS

Pierre Savatier discussing his recent results on inter-species chimeras, including those based on rabbit blastocysts, and based on primate (human and non-human) naive #iPSCells.

#FSSCR2025
✨🔬 Exciting #StemCell science ahead!
Lyon, Nov 17–19, 2025

Full program here 🫵
buff.ly/kLeH5ET

About Event | iPSC Drug Development Summit The 5th iPSC Drug Development Summit is the longest-standing and most comprehensive meeting focused exclusively on iPSC-derived therapies

I'm excited to announce the 5th iPSC Drug Development Summit (Oct 1–2, 2025, Boston), the industry’s leading forum advancing iPSC-derived therapies hosted by Hanson Wade.

ipsc-therapies-summit.com/about/about-...

#ipscells #drugdiscovery #drugdevelopment

14/16 Future approaches promise even greater precision.

Stanford researchers combine induced pluripotent stem cells with CRISPR gene editing to create scalable tissue replacements.

CRISPR offers more targeted correction than viral gene addition, with fewer side effects.

#CRISPR #iPSCells

iPS cell transplants show early promise for treating Parkinson's disease safely In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with Parkinson’s disease and observed promising motor improvements with no serious ...

iPS cell transplants show early promise for treating Parkinson's disease safely 🧠🧬💉 www.news-medical.net/news/2025042... #Parkinsons #StemCells #RegenerativeMedicine #Neuroscience #CellTherapy #iPSCells #Dopamine #Neurodegeneration #TranslationalResearch @nature.com

Extensive pre-clinical testing of the safety and efficacy of midbrain dopaminergic cells derived from clinical-grade human #iPSCells lines, paving the way for an autologous clinical trail in Parkinson's disease. Harvard Medical School.
#CellTherapy
https://buff.ly/4ia51Se

Wow! Another phase III clinical trial using #iPSCells derived cells, for Parkinson's disease.

Allogeneic CAR NK cells derived from #iPSCells in lymphoma (phase I trial): safe and impressive results for follicular lymphoma, as well as for relapsed LBCL after autologous #CARTcells.
Towards a ready-to-use CART treatment?

Autologous #iPSCells production at Cira for $316,000, and 50x less in 10 years.

This is exciting progress to see for #ipscells!

Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease - Nature Medicine Sustained safety outcomes were seen at 2-year follow-up after induced pluripotent stem cell-derived mesenchymal stromal cell infusion in 15 individuals with steroid-resistant acute graft-versus-host…

In a 2-year follow-up of a trial on iPS cell-derived MSCs for steroid-resistant acute graft-versus-host disease, 60% of 15 participants survived, highlighting its potential. #iPScells #GvHD PMID:38778211, Nat Med 2024, @NatureMedicine

First-in-human using allogeneic #iPSCells in four patients with cornea defect (limbal stem-cell deficiency LSCD)! And it works! No clinical rejection, disease stage had improved, and visual acuity was enhanced. A larger clinical trial is planned.
In the Lancet
https://buff.ly/4fhik2f
#CellTherapy

Rabbit naive #iPSCells can colonize rabbit blastocysts and create highly chimeric rabbit fetuses. A new tool to study the determinant of embryonic colonization-competence. By Nathalie Beaujean, Pierre Savatier, Marielle Afanassieff and colleagues.
t.co/4itGOlLK93

Still no commercialized cell therapies derived from #iPSCells (ATMP), but the field is dynamic with numerous clinical trials underway.

Very nice inventory by Cade Hildreth. ⤵️

bioinformant.com/ipsc-derived...